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Felty syndrome is a rare disease defined by neutropenia,splenomegaly, and rheumatoid arthritis. Sometimes the differentialdiagnosis between Felty syndrome and large granular lymphocyte
leukemia is problematic. Recently, somatic STAT3 and STAT5B muta-
tions were discovered in 30-40% of patients with large granular lympho-
cyte leukemia. Herein, we aimed to study whether these mutations can
also be detected in Felty syndrome, which would imply the existence of
a common pathogenic mechanism between these two disease entities.
We collected samples and clinical information from 14 Felty syndrome
patients who were monitored at the rheumatology outpatient clinic for
Felty syndrome. Somatic STAT3 mutations were discovered in 43%
(6/14) of Felty syndrome patients with deep amplicon sequencing target-
ing all STAT3 exons. Mutations were located in the SH2 domain of
STAT3, which is a known mutational hotspot. No STAT5B mutations
were found. In blood smears, overrepresentation of large granular lym-
phocytes was observed, and in the majority of cases the CD8+ T-cell
receptor repertoire was skewed when analyzed by flow cytometry. In
bone marrow biopsies, an increased amount of phospho-STAT3 positive
cells was discovered. Plasma cytokine profiling showed that ten of the
92 assayed cytokines were elevated both in Felty syndrome and large
granular lymphocyte leukemia, and three of these cytokines were also
increased in patients with uncomplicated rheumatoid arthritis. In con-
clusion, somatic STAT3 mutations and STAT3 activation are as frequent
in Felty syndrome as they are in large granular lymphocyte leukemia.
Considering that the symptoms and treatment modalities are also simi-
lar, a unified reclassification of these two syndromes is warranted.
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ABSTRACT
Introduction
Felty syndrome (FS) is a disease defined by neutropenia, splenomegaly, and
rheumatoid arthritis (RA). It affects less than 1% of RA patients.1 A classical FS
patient has long-standing RA, unexplained neutropenia (causes such as
antirheumatic drugs must be ruled out), and splenomegaly. Splenomegaly is not an
absolute criterion for diagnosis.1 The disease has much in common with T-cell large
granular lymphocyte (T-LGL) leukemia, an indolent chronic hematological malig-
nancy in which patients have persistent monoclonal LGL lymphocytosis
>0.5x109/l, which in the majority of cases consists of CD8+ T cells. Concomitant
autoimmune manifestations such as neutropenia (70-80% of cases), RA (11-36%),
and splenomegaly (20-60%) are also observed.2
Recent studies have unveiled the molecular pathogenesis of LGL leukemia;
somatic STAT3mutations in lymphocytes leading to constitutive STAT3 activation
occur in 30-40% of LGL leukemia patients.3-6 Similar mutations have also been dis-
covered in the STAT5B gene in 2% of cases.7 STAT3muta-
tion status is closely linked to RA in LGL leukemia;
patients with multiple STAT3 mutations have RA (43%)
more frequently than patients without mutations (6%).6
Due to the similarity of clinical and laboratory findings,
the differential diagnosis of LGL leukemia with RA and FS
may sometimes be difficult. Past studies have shown a
resemblance in patient phenotypes, responses to treat-
ment, high HLA-DR4 prevalence, and analogous findings
in splenectomy samples.2 Furthermore, both diseases are
treated with immunosuppressive agents.2 Some authors
have suggested that these two diseases represent the same
entity,2,8,9 but this hypothesis currently lacks molecular evi-
dence. Herein, we utilized deep next-generation sequenc-
ing (NGS) of STAT3 and STAT5B genes and cytokine pro-
filing in order to examine if these two diseases are part of
the same disease continuum.
Methods
All methods are described in more detail in Online Supplementary
Methods.
Patient recruitment
The diagnosis of FS is defined by RA, neutropenia, and
splenomegaly. We included patients with an established Felty syn-
drome diagnosis (n=14) stated in patient records. In addition, sam-
ples from healthy controls (n=8), RA patients without Felty syn-
drome (n=20) and LGL leukemia patients (n=9) were used. The
ethical boards of our institutions approved the study, and the
Declaration of Helsinki guidelines were followed. Patients gave
written informed consent. 
Sample preparation
DNA samples from different cell types were obtained (Online
Supplementary Table S1 and Online Supplementary Figure S1). For six
FS patients, only archived samples were available (Online
Supplementary Table S1). Eight FS patients gave fresh peripheral
blood samples. Mononuclear cells were extracted via Ficoll gradi-
ent centrifugation (Ficoll-Paque PLUS, GE Healthcare) from fresh
blood samples and CD4+ and CD8+ cells with magnetic bead selec-
tion (Miltenyi Biotech). DNA was extracted according to manu-
facturer’s instructions using the NucleoSpin Tissue DNA extrac-
tion kit (Macherey-Nagel).
T-cell clones were investigated with flow cytometry using a
panel of antibodies against the different variable β regions of the
T-cell receptor (IO Test VβMark Kit, Beckman Coulter), accompa-
nied by anti-CD3 (SK7), anti-CD4 (SK3), and anti-CD8 (SK-1)
(Becton Dickinson) antibodies. The IO Test Vβ mark kit covers
approximately 70% of the Vβ T-cell repertoire.  Sorting of expand-
ed CD8+ T-cell populations was performed using the same anti-
bodies. 
STAT3 and STAT5B sequencing
Amplicon sequencing of 23 exons of the STAT3 gene, STAT5B
exon 16, and STAT5A exon 17 was performed on the DNA sam-
ples. Amplicon sequencing is a polymerase chain reaction (PCR)-
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Figure 1. Felty syndrome patients harbor STAT3 mutations. (A) STAT3 mutations (presented as protein level amino acid changes) identified in study patients.
Mutation variant-allele frequencies (VAFs) in the sample with the highest VAF are shown in the table. All samples and mutations detected are shown in Online
Supplementary Table S1. (B) Schematic of sequencing results of all six patients with STAT3 mutations. Each patient is presented separately, and the presence of a
mutation is indicated by -/+. Presented in smaller font are the data on the VAF and the sample type that was available for sequencing from the time-points. DNA
sample types in A-B: Bone marrow (BM) cells, cultured cells from the BM (originally obtained for chromosome analysis); BM MNC: bone marrow mononuclear cells;
PWB: peripheral whole blood; PB CD8+: peripheral blood CD8+ cells. 
A
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based NGS method that enables very high sequencing depths (up
to over 100,000x). It detects variants with low variant-allele fre-
quencies (VAF), locally reaching a sensitivity of 0.5%.6 Sequencing
was performed using the Illumina MiSeq System, and the data
analysis pipeline has been described in more detail previously.6
Herein, we considered the mutation to be true if it occurred in the
sequenced sample with a VAF >1% and absent in control samples.
All primers are listed in Online Supplementary Table S2.
Cytokine profiling
Ethylenediaminetetraacetic acid (EDTA) plasma samples from
eight healthy controls, nine RA patients, seven FS patients, and
nine LGL leukemia patients were analyzed with the Proseek
Multiplex Inflammation I (Olink Biosciences) immunoassay
which detects 92 different biomarkers simultaneously in one sam-
ple via oligonucleotide-labeled antibodies. The target-antibody
complexes are detected with real-time PCR. A list of the analyzed
biomarkers is presented in Online Supplementary Table S3. The
assay does not report protein concentrations, and the results are
reported as normalized protein expression units (NPX). 
Immunohistochemistry
To study phosphorylation of STAT3, we stained bone marrow
biopsy samples from seven FS patients with anti-phospho-STAT3
(Tyr705) and anti-CD57 antibodies. We also used 14 control bone
marrow samples, which had been taken to examine abnormal
blood counts, but no specific diagnosis had been achieved. 
Statistics
Multiplex cytokine data was analyzed as NPX values with
Qlucore Omics Explorer (Qlucore). Cytokines with a false discov-
ery rate <0.1 (Benjamini-Hochberg method) were reported, and
further post hoc testing was performed using Dunn’s multiple com-
parison tests. Statistical analyses for the clinical data were per-
formed with GraphPad Prism software. Statistical tests included
the Kruskal-Wallis omnibus test, Dunn’s multiple comparison test,
Mann-Whitney test and Fisher’s exact test.
Results
Patient characteristics 
The clinical characteristics of the 14 FS patients included
herein are presented in Table 1 and Table 2, and Online
Supplementary Table S4 and Online Supplementary Table S5.
None of the patients represented classical LGL leukemia
with marked LGL lymphocytosis and T-cell receptor
(TCR) γ gene rearrangement. Thirteen patients had long-
standing RA prior to Felty syndrome diagnosis, and they
had been treated with immunosuppressive drugs at the
time of sample collection. The first sample of patient 9
was taken before initiating immunosuppressive treat-
ment. 
As LGL lymphocytosis is the hallmark of LGL leukemia,
peripheral blood smears were re-examined for this study.
FS patients showed an overrepresentation of LGL lympho-
cytes (Table 2; normal range up to 25% of lymphocytes),
but only two patients (patients 3 and 6) had absolute LGL
lymphocytosis. Patients’ bone marrow exams did not
show dysplasia, but they often showed a slight left shift in
granulopoiesis, and in some cases, overrepresentation of
lymphocytes.
Large CD8+ T-cell expansions are characteristic for 
P. Savola et al.
306 haematologica | 2018; 103(2)
Table 1. Basic clinical characteristics of Felty syndrome patients.
Patient ID Sex Age at RA Felty Infections Serostatus Erosions Active arthritis Splenomegaly Other extra-articular
sample duration dg at sample symptoms
collection collection
1 M 76 15 6 3 pos no no yes 15cm rheumatoid nodules
2 F 49 17 5 0 pos yes no yes no
3 F 71 10 0 1 pos yes no yes 16cm weight loss
4 F 63 10 0 0 pos yes no (1 s) yes 13cm rheumatoid nodules
5 F 72 23 2 5 pos yes no no 11cm weight loss, rheumatoid 
nodules
6 F 71 24 0 0 pos no yes (1s, 1t) no 10cm no
7 F 68 54 22 1 neg* yes yes (1s, 1t) yes 17cm leg ulcer
8 M 71 21 21 0 pos yes no yes 13cm no
9 F 65 0 0 1 pos no yes (>5s, >2t) yes 17cm fever, chills, cough
10 F 64 10 0 5 pos yes Yes >3s yes weight loss, 
maculopapular rash
11 F 57 24 0 1 pos yes no no fever
12 M 40 3 0 0 unknown no no no persistent rash
13 F 70 42 7 10 pos yes no yes 14cm leg ulcer, weight loss
14 F 38 5 0 0 pos yes yes no no
Summary 79% F, 66.5 16.0 0 1 92% pos, 71% yes, 36% yes, 64% yes, 
21% M (55.0-71.0) (8.8-24.0) (0.0-6.3) (0.0-3.5) 8% neg 29% no 64% no 36% no
Clinical characteristics of the patient cohort. Summaries of the parameters are shown on the bottom row. Age, RA duration, Felty diagnosis (dg), and infections are summarized
as medians with interquartile ranges in parenthesis. The patients’ ages are shown as ages at the time of the first sample collection. RA duration is shown as years of RA prior to
collecting the first sample for the study. Felty dg is shown as years, starting from FS diagnosis to the collection of the first sample. The number of infections requiring hospitaliza-
tion is shown. Serostatus was defined as either elevated rheumatoid factor and/or anti-citrullinated protein antibodies (ACPAs). Erosions were defined via hand and feet x-rays.
The number of swollen (s) and tender (t) joints at sample collection is shown in parenthesis. Spleen size was measured with ultrasonography. *Rheumatoid factor normal, how-
ever, ACPAs were not determined. ID: identity; ND, not determined; RA: rheumatoid arthritis. 
T-LGL leukemia.4 In FS patients, flow cytometry screening
revealed skewed CD8+ TCR Vβ usage (Table 2 and Online
Supplementary Figure S2). In 40% (4/10) of the examined
cases, CD8+ expansions comprised over 20% of all CD8+
T cells.
Most of our patients’ clinical features were well in
accordance with the FS criteria (Table 1 and Table 2). Only
three patients did not show the classical phenotype. No
neutropenia was recorded in the clinical registry of patient
8. Patient 9 had cytopenias during tuberculosis therapy
(although neutropenia continued years after the comple-
tion of the therapy). In addition, patient 3 showed lym-
phocytosis, but her bone marrow and peripheral blood
TCRγ rearrangement tests were negative, and flow cytom-
etry did not show any excess of natural killer (NK) cells. 
Somatic STAT3 mutations were identified in 43% of
patients
For many patients, several sample types and samples
from multiple time-points were available for sequencing
(Online Supplementary Table S1). STAT3mutations occurred
in 43% (6/14) of FS patients (Figure 1A,B). One patient had
two different STAT3 mutations (N647I and Y640F).  In all
assessable cases, STAT3 mutations occurred in CD8+ cells
but not in CD4+ cells. In 4/6 STAT3-mutated cases, the
mutations were detected in multiple sample types, where-
as in 2/6 patients the mutation was detected only in one
sample (Figure 1B and Online Supplementary Table S1). Five
STAT3-mutated patients had follow-up samples available,
and in three cases the mutations were also detected during
the follow-up (Figure 1B). None of the patients had
STAT5B mutations.
When patients with STAT3 mutations were compared
with patients with no STAT3 mutations, no differences
emerged in age, sex, LGL counts, CD8+ Vβ clone size, neu-
tropenia duration (adjusted for laboratory follow-up time),
lymphopenia duration (adjusted for laboratory follow-up
time), highest and lowest lymphocyte counts, duration of
RA, or the number of infections (compared with Mann-
Whitney test). No statistically significant differences
occurred in TCRγ rearrangement status, existence of ero-
sions, splenomegaly, or active arthritis status (compared
with Fisher’s test).
Sorting of expanded CD8+ T cells with flow cytometry
using Vβ antibodies showed that patient 6 harbored the
Y640F mutation in the major expanded CD8+ T-cell popu-
lation (Vβ3) (Figure 2), but no STAT3 mutations were
found in CD4+ cells or other CD8+ cells lacking Vβ3. A
similar analysis was also performed with the sample of
patient 4, but the mutation was not located in the largest
CD8+ T-cell expansion (Vβ22) which was detectable by
flow cytometry (Figure 2). The sum of all of the detected
CD8+ T-cell expansions made up only 38% of all CD8+ T
cells, which is clearly less than the anticipated level of
70% of the TCR repertoire (Online Supplementary Figure
S3). This suggests that the sensitivity of flow cytometry is
insufficient to detect all clones.  An 'undetected' clone is
likely to harbor the identified mutation, since the VAF of
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Table 2. Laboratory findings of Felty syndrome patients.
Patient ID LGL TCRγ STAT3 CD8+ Lab Neutropenia Lowest Lymphopenia Lowest Highest Thrombocytopenia
count assay mutation expansion follow-up duration neutrophil duration lymphocyte lymphocyte duration
positive? (% of CD8+) count count count
1 33%/0.20 no yes ND 163 94 0.17 135 0.28 1.52 18
2 ND no yes 7.6 210 73 0.4 191 0.5 1.74 0
3 62%/0.86 no yes 13.9 156 14 0 0.07 1.37 4.96 0.2*
4 30%/0.42 yes: PB yes 10.6 115 3 <0.05 4 1.03 2.93 2.8
5 28%/0.34 no yes ND 52 18 <0.05 38 0.41 0.46 2
6 69%/0.57 yes: BM yes 21.7 189 103 0.66 63 0.82 2.42 0
7 ND ND no ND 207 32 1.22 194 0.34 0.64 204
8 ND ND no 25.5 180 ND 1.58 173 0.7 1.33 394**
9 28%/0.29 no no ND 144 33 0.08 61 0.79 1.82 0
10 ND yes no 52.4 4 4 1.14 4 0.75 1.25 4
11 ND equivocal no 17.2 11 11 1 2 0.9 1.6 11
12 ND no no 6.3 5 3 1.1 3 0.8 1.5 2
13 36%/0.26 ND no 27.8 119 33 0 88 0.4 1.82 0
14 ND ND no 8.8 62 16 0.6 57 0.4 1.3 0
Summary 33%/0.34 33% yes 43% yes, 15.6 131.5 18 0.5 59 0.73 1.6 2
(28-62)/ 67% no 57% no (8.5-26.1) (41.8-182.3) (7.5-53) (0-1.1) (3.8-144.5) (0.4-0.84) (1.3-2.0) (0-9.3)
(0.26-0.57)
The table shows the laboratory findings of Felty syndrome patients. The bottom row shows summary statistics for all patients (when applicable): median and interquartile range
in parenthesis. All blood cell counts are shown as 109/l. The patients’ peripheral blood (PB) smears were, where possible, re-examined for this study, and LGL cells were counted
as percentage of lymphocytes (counting 300 lymphocytes). Absolute LGL counts (109/l) were calculated from lymphocyte counts. The sizes of CD8+ T-cell expansions were stud-
ied via flow cytometry. Laboratory follow-up time in months (Lab follow-up) was calculated. The cumulative durations of neutropenia (<1.5x109/l), lymphopenia (<1.3x109/l),
and thrombocytopenia (<100x109/l) were calculated as months from laboratory records. Of note, patients 10 and 12 have laboratory follow-up only for the period before hema-
tology referral, but oral history indicates a history of years (patient 10) and decades (patient 12) of leukopenia. *HIT: heparin-induced thrombopenia, not included in summary
statistic calculations. **Thrombocytes 100-150, not included in summary statistic calculations. ND: not determined; LGL: large granular lymphocyte; TCRγ: T-cell receptor γ; BM:
bone marrow.
the mutation was high in the CD8+ Vβ22-negative fraction
(18.8%).
Previously, we have studied the presence of STAT3
mutations in 82 newly diagnosed RA patients, and no
mutations were detected.10 Herein, we sequenced the
STAT3 hotspot exon 21 from RA patients who had been
treated for several years with no evidence of FS (n=14). As
in newly diagnosed RA, no STAT3mutations were detect-
ed in this patient cohort. The patients are described in
more detail in Online Supplementary Table S6. 
FS patients have increased phosphorylation of STAT3
in bone marrow samples
We had access to seven bone marrow biopsy samples
from FS patients 1-6 and 9. Patients 1-6 harbored somatic
STAT3 mutations (Figure 1). Immunohistochemical stain-
ing of the samples showed increased amounts of phos-
pho-STAT3 positive cells in FS patients when compared to
the controls (Figure 3).  The degree of phosphorylation
was not associated with mutation VAFs: patient 3 did not
have mutations in bone marrow samples, nonetheless the
P. Savola et al.
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Figure 2. Sequencing of sorted, expanded CD8+ T-cell populations. The expanded CD8+ T-cell populations that were detected by the initial Vβ flow cytometry screen
were sorted via flow cytometry and sequenced with Amplicon sequencing (n=2; patients 4 and 6). (A) Gating strategy for Vβ analysis. The subpopulation of interest
was included in subsequent gates and other populations were excluded. (B) The expanded CD8+ clones in patients 6 and 4. The expanded clones expressing the Vβ
in question, as well as all other CD8+ cells were collected and sequenced. (C) The summarized sequencing results of sorted cells. The small number of mutation-
positive cells present in the CD8+Vβ 3neg  cells of patient 6 are likely due to sorting impurities. APC: allophycocyanin; FSC: forward scatter; FITC: fluorescein isothio-
cyanate; VAF: variant-allele frequencies.
A
B
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bone marrow biopsy showed marked STAT3 phosphory-
lation. Additionally, patient 9 showed STAT3 phosphory-
lation in the bone marrow despite the absence of STAT3
mutations. Overall, CD57+ cells were less abundant than
phospho-STAT3+ cells (Figure 3).
Felty syndrome patients shared similar plasma
cytokine profiles with LGL leukemia and RA patients
Previous reports have shown that LGL leukemia
patients have aberrant levels of several cytokines in their
plasma.11-17 Analysis via a multiplex cytokine panel
showed significant differences between healthy controls
and patients with immune-mediated disease (RA, Felty
syndrome, LGL leukemia). Only minor differences
emerged between individual disease conditions (Figure 4).
Many plasma cytokines (10/92; colony stimulating factor
1 (CSF1), C-X-C motif chemokine 10 (CXCL10), inter-
leukin (IL)-15RA, macrophage inflammatory protein 1-α
(MIP-1-α), oncostatin-M (OSM), tumor necrosis factor
receptor superfamily member 9 (TNFRSF9), programmed
cell death 1 ligand 1 (PD-L1), CUB domain-containing pro-
tein 1 (CDCP1), IL-6, and hepatocyte growth factor
Somatic STAT3 mutations in Felty syndrome
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Figure 3. Felty syndrome patients show
STAT3 phosphorylation in bone marrow.
Representative immunohistochemical
analysis of phospho-Tyr705-STAT3 (red)
and CD57 (green) in bone marrow tissue
samples of Felty syndrome (n=7) and con-
trol samples (n=14) counterstained with
hematoxylin. All images presented in the
figure are 40x magnified unless otherwise
specified. Felty syndrome patients show
more phosphorylated STAT3 than controls,
but the amount of phosphorylation was not
related to the STAT3 mutation VAFs. Patient
numbers and mutation status are present-
ed in the figure.
(HGF)) were elevated in both FS and LGL leukemia (Online
Supplementary Figure S4). CDCP1, IL-6, and HGF were ele-
vated in all three diseases. RA patients shared some char-
acteristics with FS and LGL leukemia patients, but seven
cytokines were statistically significantly elevated only in
RA patients and not in other patients (Online
Supplementary Figure S4). Clinical information on the LGL
leukemia patients, RA patients, and healthy controls used
in this assay is shown in Online Supplementary Table S7 and
Online Supplementary Table S8.
When STAT3-mutated patients were compared with
patients without STAT3 mutations, only CXCL1 was sta-
tistically significantly elevated in plasma samples of
STAT3-mutated patients (Online Supplementary Figure S5).
However, there was no significant difference when com-
pared to healthy controls. 
Discussion
Previous studies have shown that Felty syndrome and
LGL leukemia share many clinical features.2 The study
herein confirms that in addition to similar clinical aspects,
these two disease entities also share analogous patho-
genetic molecular markers. In a cohort of 14 FS patients,
STAT3 mutations were discovered in 43% of the cases.
This is comparable with the STAT3mutation frequency in
LGL leukemia.4-6 
The diagnostic criteria for FS are not specific. Therefore,
our study patients are a heterogeneous group, which may
be subject to criticism. However, these patients represent
the clinical spectrum of the FS patients who are monitored
at rheumatology outpatient clinics. Further, most of our
patients’ clinical features were in accordance with the FS
diagnostic criteria. 
All detected mutations occurred in the hotspot exon 21 in
the SH2 domain of STAT3. Likewise, as in LGL leukemia,
Y640F and D661 mutations were the most common.4-6
Further, STAT3mutations occurred in CD8+ cells and not in
CD4+ cells in the cases in which this could be assessed.
Interestingly, we also observed increased STAT3 activation
in the bone marrow samples of FS patients. The presence of
phospho-STAT3+ cells was not related to STAT3 mutation
status. Similarly, it has been shown in LGL leukemia that
STAT3 is activated in the majority of patients,5,18,19 although
STAT3 mutations only occur in 30-40% of patients.4-6 In
P. Savola et al.
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Figure 4. Felty syndrome patients have a similar cytokine profile as that of LGL leukemia. The heatmap compares the plasma cytokine profiles of healthy controls,
RA patients, Felty syndrome patients, and LGL leukemia patients. Data was analyzed as NPX units, and were normalized to allow for coloring on the same scale for
the heatmap. Bright blue represents smaller protein concentration, while bright yellow represents higher protein concentration. The heatmap shows all cytokines for
which the Q-value (false discovery rate) was less than 0.1. RA: rheumatoid arthritis; LGL: large granular lymphocyte.
α
β
addition to LGL leukemia, somatic STAT3 mutations have
been described in other disease conditions, such as aplastic
anemia, myelodysplastic syndrome, T-cell lymphomas, and
inflammatory hepatocellular adenoma.20 In addition, one
case report has shown STAT3 mutations in Felty
syndrome.21 Of note, we did not detect any STAT3 muta-
tions in patients with chronic RA who had no evidence of
FS. This is concordant with our previous findings showing
that in a cohort of 82 newly diagnosed RA patients, no
STAT3mutations were detected.10
LGL lymphocytosis is a hallmark of LGL leukemia.
Peripheral blood smear re-examinations revealed overrep-
resentation of LGL cells in FS patients. Despite the high
percentages of LGL cells, only two of our patients had
LGL lymphocytosis (>0.5*109/l; patients 3 and 6). Absolute
lymphocyte counts were low, excepting one patient. A
previous study, which defined LGL cells with flow cytom-
etry, reported increased percentages of LGL cells in FS.22
This is concordant with our data. Our patients’ skewed
TCR Vβ usage also indicates that large T-cell clones often
exist in FS, but the expansions were smaller when com-
pared with results obtained with the same antibody panel
in T-LGL leukemia.4 More detailed clonality analysis
would require TCR deep sequencing. 
The smaller T-cell clone sizes in FS patients when com-
pared to LGL leukemia patients could also explain why
the STAT3 mutation VAFs were generally lower in FS
patients. The VAF is highly dependent on the proportion
of  cells harboring mutations in the sequenced sample, and
smaller clone sizes result in smaller detected VAFs. We had
CD8+ cells available from 4/6 patients with STAT3 muta-
tions, and even these cell fractions had low VAFs (1-1.4%),
barring one case (8.8%). However, some LGL leukemia
patients also harbor clones with small (0.8%) VAFs.6 Thus,
our results do not differ from LGL leukemia cases with
oligoclonal TCR expansions. Therefore, we suggest that
LGL leukemia and FS form a disease continuum, which
could explain the differences in VAFs and clone sizes.
Many plasma cytokines (10/92) were elevated both in
FS and LGL leukemia when compared to healthy controls
(such as IL-15RA, CXCL10 and PD-L1). Importantly, only
three of them were also elevated in RA patients (CDCP1,
IL-6, and HGF). Furthermore, our results confirm the pre-
vious findings of increased IL-15RA, IL-8, C-C motif
chemokine ligand 4 (CCL4=MIP1-β), and CXCL10 in LGL
leukemia.11,12,14 Of these cytokines, IL-15RA and CXCL10
were also elevated in FS. Although some differences
emerged between the diseases, we discovered that the
three immune-mediated diseases are not strikingly differ-
ent in terms of cytokine profiles. This is not unexpected;
many LGL leukemia patients have RA, comparative to the
other patient groups. 
In this small study, patients with STAT3 mutations did
not differ from patients without STAT3mutations in terms
of clinical or biochemical characteristics. In LGL leukemia,
neutropenia and RA are more common in patients with
mutations.4,5 Similarly, germline gain-of-function STAT3
mutations lead to early-onset multiorgan autoimmunity,
including cytopenias.23-25 However, the exact mechanism
of neutropenia in LGL leukemia and FS is not clear. Based
on the current hypothesis, STAT3mutations lead to clonal
outgrowth.26 Depending on the antigen target, the lym-
phocyte clones can attack bone marrow and joints. In
addition, disease manifestations may also result from the
production of proinflammatory cytokines mediated by
hyperactive STAT3 signaling.27 Thus, the activation of
STAT3 is a likely causative factor for autoimmunity, but
future research needs to address the exact mechanisms in
more detail.
Of note, four of the FS patients had celiac disease,
despite the fact that RA (without FS) does not have an
established connection with celiac disease. Although the
observed overrepresentation may occur by chance, celiac
disease could also be a result of chronic systemic immune
dysregulation. This is strengthened by recent findings
showing that activating STAT3 mutations can be detected
in refractory celiac disease patients’ duodenal biopsy-
derived intraepithelial lymphocyte cell lines.28 The consti-
tutive STAT3 activation of immune cells may contribute
to the persistent autoimmune inflammation that occurs in
these patients. A similar mechanism is possible in FS
patients, but this issue requires further investigation.
In conclusion, our results supplement the evidence that
FS and LGL leukemia belong to the same disease continu-
um and diagnostic group. These diseases share similar
molecular pathogenetic features and phenotypes, and are
treated similarly with immunosuppressive agents. Thus,
unified re-classification of these two diseases should be
considered.
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